| Code | CSB-RA621767MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Leiolizumab, targeting SELPLG (selectin P ligand glycoprotein 1), also known as PSGL-1 or CD162. SELPLG functions as a critical cell surface glycoprotein that mediates the initial tethering and rolling of leukocytes on activated endothelium during inflammatory responses. Through its high-affinity binding to P-selectin and E-selectin, SELPLG orchestrates leukocyte trafficking and recruitment to sites of inflammation and tissue injury. Dysregulated SELPLG expression and signaling have been implicated in various pathological conditions, including chronic inflammatory diseases, autoimmune disorders, cardiovascular disease, and cancer metastasis, where it facilitates tumor cell adhesion to the vasculature.
Leiolizumab represents an investigational therapeutic antibody designed to block SELPLG-mediated interactions, thereby modulating inflammatory cell recruitment and adhesion cascades. This biosimilar antibody provides researchers with a valuable tool for investigating SELPLG biology, exploring leukocyte-endothelial interactions, examining inflammatory pathway mechanisms, and evaluating potential therapeutic strategies targeting selectin-mediated adhesion in preclinical disease models.
There are currently no reviews for this product.